Glucotrack (GCTK) Non-Current Debt (2010 - 2025)

Glucotrack (GCTK) recorded quarterly Non-Current Debt of $227000.0 in Q3 2025, up 2.71% on a QoQ basis from $221000.0 in Q2 2025.

Glucotrack (GCTK) Non-Current Debt (2010 - 2025) Analysis & Trends

Glucotrack has disclosed Non-Current Debt across 15 years of filings, most recently posting $227000.0 for Q3 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $227000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $227000.0 (changed N/A YoY) and the FY2024 annual result came in at $203000.0, changed N/A from the prior year.
Non-Current Debt grew to $227000.0 in Q3 2025, from $221000.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $227000.0 in Q3 2025 and troughed at $191000.0 in Q3 2022.
A 4-year average of $203000.0 and a median of $201000.0 in 2021 frame the typical range for Non-Current Debt.
Biggest YoY gain for Non-Current Debt was 7.29% in 2022; the steepest drop was 7.14% in 2022.
Tracing GCTK's Non-Current Debt over 4 years: stood at $210000.0 in 2021, then slipped by 7.14% to $195000.0 in 2022, then grew by 4.1% to $203000.0 in 2024, then grew by 11.82% to $227000.0 in 2025.
Business Quant data shows GCTK's Non-Current Debt at $227000.0 in Q3 2025, $221000.0 in Q2 2025, and $201000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	-
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	14.71 Bn
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	12.50 Bn
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	-
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	202.80 Mn
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	4.58 Bn
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	1.86 Bn
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	-
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	8.62 Bn
10	Glucotrack	4.26	-7.38 Mn	-	-

Download Data